Advicenne SA (FR0013296746)
XSTU 
Summary
FR0013296746 Chart
Advicenne SA (FR0013296746) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Advicenne SA ever had a stock split?
Advicenne SA Profile
| Biotechnology Industry | Healthcare Sector | Mr. Didier Laurens CEO | XSTU Exchange | FR0013296746 ISIN |
| France Country | 21 Employees | - Last Dividend | 2 Jul 2025 Last Split | - IPO Date |
Overview
Advicenne S.A. is a specialty pharmaceutical company focused on the development, commercialization, and marketing of treatments for rare renal diseases. Founded in 2007 and based in Paris, France, the company has established a niche in addressing the unmet medical needs within the realm of nephrology. Advicenne's strategic efforts are concentrated on advancing its pipeline of innovative drug candidates and leveraging its expertise to enrich its product portfolio, primarily aiming to improve the lives of patients afflicted by rare renal disorders.
Products and Services
Sibnayal: Advicenne's flagship product, Sibnayal, stands out as a prominent drug candidate that has successfully completed its phase III clinical trial. Specifically designed for the treatment of distal renal tubular acidosis (dRTA), a rare kidney disorder, Sibnayal exemplifies the company's commitment to tackling renal diseases with significant patient impact. In addition to dRTA, Sibnayal has shown potential in tackling cystinuria, another challenging renal condition, highlighting its versatility and robust therapeutic potential.
Likozam: Within Advicenne's product lineup, Likozam is formulated as a unique version of clobazam. This medication is tailored for the treatment of short-term symptomatic relief of severe and disabling anxiety, or anxiety that causes significant distress to the patient. Likozam's inclusion in Advicenne’s portfolio underscores the company’s efforts to address a broader spectrum of neurological conditions beyond its primary focus on renal diseases.
Levidcen: Advancing its commitment to neurological conditions, Advicenne also offers Levidcen, a specialized galenic form of levetiracetam. This product is targeted at the management and treatment of epileptic seizures, showcasing the company's capacity to diversify its therapeutic offerings. Levidcen represents Advicenne's foray into epilepsy management, indicating a strategic expansion of its pharmaceutical repertoire to encompass a wider range of neurological disorders.
